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Introduction
The Fas/FasL system is considered to be the most efficient start point of the apoptosis extrinsic pathway, and therefore plays a crucial role in the regulation of cell death and survival [1] . It www.fhc.viamedica.pl (FasL, CD95L, CD178) and its cell surface membrane receptor, Fas (FasR, CD95, APO-1). FasL is a protein existing both in a soluble (sFasL) and a cell membrane-bound form. Fas is expressed as a member of the tumor necrosis factor family of surface receptors; binding of FasL to Fas results in apoptosis of susceptible cells [2] . The process is particularly effective if FasL molecules form trimers. The Fas/FasL system is involved in the pathomechanisms of immunity and inflammation, including lymphocyte-dependent cytotoxicity, alloreactive T cells clonal deletion, virally infected or cancer cells removal as well as activation induced cell death (AICD) of T lymphocytes [3, 4] . Elevated serum sFasL concentrations have been observed in malignant and inflammatory diseases [5] . Fas is expressed by multiple cell and tissue types, whereas Fas Ligand is expressed mostly in activated T cells. It is active as one of the major effector molecules in natural killer cells and cytotoxic T lymphocytes, in particular CD8 T cells, CD4 T helper 1 (Th1) cells [6] . Consequently, in septic shock, the Fas/FasL system has been regarded as a potential therapeutic target [2] .
In airways, FasL involvement was first established in the pathogenesis of acute lung injury (ALI). Matute-Bello et al. were the first to suggest in 1999 that massive release of sFasL within the respiratory system of ALI patients might trigger severe epithelial damage characteristic for ARDS [7] . Since then, the essential role of the Fas/FasL pathway in the development of lower airways apoptosis, with subsequent alveolar epithelial injury in, has been well confirmed in experimental models of lung inflammation/injury with lpr (i.e. Fas deficient) mice as well as in clinical studies with ALI and ARDS patients [8] [9] [10] [11] .
In contrast, the significance of FasL in chronic lower airways disorders, like interstitial lung diseases (ILDs), has not been extensively evaluated. Kuwano et al. reported an increased concentration of sFasL in BAL supernatants from patients with interstitial pneumonia associated with collagen vascular diseases (CVD-IP) and with bronchiolitis obliterans organizing pneumonia [12] . In IPF group, sFasL levels were relatively higher, but the difference compared to controls did not reach statistical significance. Nevertheless, BAL sFasL level was proposed as a useful decision marker for systemic corticosteroid therapy in IPF and CVD-IP patients [13] .
Recent studies have revealed that while both forms of FasL, soluble and membrane-bound, are capable of inducing the apoptotic process, sFasL has a relatively weak pro-apoptotic effect and might actually down-regulate the activity of membrane Fas receptors [1, 14] . Thus, membrane-bound FasL expressed on cytotoxic cells seems to be more active in apoptosis induction than expected, due to facilitated trimerization of FasL molecules and more efficient Fas receptors ligation. In general, the role of FasL is potentially much more complex. For instance, experimental models of lung allogeneic grafts have indicated Fas ligand as a tool for immune suppression and tolerance [15] .
Nevertheless, it is commonly accepted that chronic inflammatory events in lower airways, occurring in ILDs, may result in epithelial damage followed by pathological reparation, fibroblast proliferation and disseminated lung fibrosis. This process is triggered by multiple proapoptotic factors, with Fas Ligand regarded as one of the most powerful [16] . The fatal ILD complication, lung fibrosis, occurs as an irrevocable consequence of idiopathic pulmonary fibrosis (IPF), while in other ILD entities it is less frequent, as in NSIP or pneumoconiosis, or quite uncommon, as in Th1 lymphocyte-driven hypersensitivity pneumonitis and early pulmonary sarcoidosis [17] [18] [19] .
Because of what is set out above, the present study was designed to provide insight into the Fas ligand (FasL) role in the pathomechanism of lung fibrosis in ILDs. Both Fas ligand forms, soluble as well as membrane-bound one, expressed by lower airways inflammatory cells, i.e. alveolar macrophages and lymphocytes, were analyzed in BAL material fairly representative of the local microenvironment of respiratory airways. Though the FasL functional activity was assessed indirectly, local expression was analyzed in the context of clinical data, in particular lung function tests and BAL cytoimmunological profile. We assessed reciprocal correlations between parameters characterizing FasL expression in BAL.
Material and methods
Study population. Bronchoalveolar lavage (BAL) was carried out in 145 patients with ILDs, including pulmonary sarcoidosis (PS; n = 89), hypersensitivity pneumonitis (HP; n = 12), silicosis (n = 7), asbestosis (n = 8), IPF (n = 23) and nonspecific interstitial pneumonia (NSIP; n = 6). PS and IPF patients were additionally subdivided according to their smoking status: 31 patients with PS and five with IPF were smokers. Smoking individuals with other ILDs (silicosis, asbestosis, HP and NSIP) were not enrolled into the study. PS patients with ongoing oral corticosteroid therapy (n = 9; prednisone 15-60 mp p.o. for at least three months), were analyzed separately. Otherwise, there was no history of previous systemic steroid or immune suppressive therapy in patients included in the study. BAL was performed with the informed consent of all patients as part of the routine diagnostics ( The diagnosis criteria of all examined subjects have been described previously [20] . Newly-detected PS was confirmed by typical clinical representation, a patient's specific histology (non-caseating granulomas in biopsy) and high resolution computer tomography (HRCT) findings [18] . PS patients were stratified according to conventional chest X-ray staging. HP was diagnosed on the basis of clinical data, including patient history with characteristic symptoms after allergen exposure, detection of specific antibodies in serum, typical presentation in HRCT) and results of lung function tests. In some cases, HP diagnosis was confirmed by lung biopsy. Pneumoconioses were diagnosed according to the chest X-ray standards of the International Labor Organization in subjects with professional or environmental exposure to inorganic dust, silica or asbestos, proven by anamnesis and typical findings in BAL cytology (ferrugineous bodies in asbestosis and silica dust light emission in polarized optical microscopy in silicosis) [17] . The diagnosis of IPF/UIP and NSIP was based on histological features, respectively usual interstitial pneumonia, UIP, or nonspecific interstitial pneumonia, NSIP, on lung biopsy. Pathologic pertinent negative findings were considered, and other clinical conditions associated with secondary UIP or NSIP excluded. In seven patients, the diagnosis of IPF was established without a lung biopsy, according to the consensus criteria of the American Thoracic Society and European Respiratory Society [21] .
The control group consisted of 17 subjects, nine nonsmokers and eight smokers, diagnosed for ILD, in whom complete clinical investigation, including lung function tests, chest X-rays and HRCT finally excluded lung pathology. The control subjects did not present any signs of infection or chronic lung disease and were not on corticosteroid or any medication known as a potential ILD cause. BAL performance. BAL cytology. BAL was performed acc. to European Respiratory Society guidelines, as described previously [22] . In brief, premedication with midazolam and local upper airways anesthesia with 2% lidocaine was followed by bronchofiberoscopy using an Olympus Bf20. The right lung middle lobe or left lung lingula was lavaged alternatively with a volume of 200 ml NaCl 0.9% sterile solution, instilled sequentially with four 50 ml aliquots. Then, BAL fluid fractions were retrieved by gentle suction, pooled, filtered and immediately transported to the laboratory.
Fluid recovery was calculated as the percentage of instilled volume [17, 23] . The total cell count, cell viability (trypan blue exclusion test) and differential count of BAL inflammatory cells were calculated, as described before [20] .
Enzyme-linked immunosorbent assay (ELISA) in BAL supernatants. Fas Ligand level measurement in BAL supernatant was performed by ELISA using a commercial kit (R&D, catalogue n o DFL00) according to the manufacturer's recommendations. The optical density was measured at 450 nm using spectrophotometric reader Elx800 (Biotek Instruments, Inc., USA). Fas Ligand concentration was expressed as pg/ml.
BAL immune cells phenotyping and flow cytometry (FC).
All BAL samples fulfilled the precise criteria of cytometric material acquisition and analysis [23] . Direct three-color typing was applied. In brief, BAL samples containing 50 μl of cell suspension (2-10 × 10 6 cells/ml) were incubated with saturating amounts of mouse, fluorochrome-conjugated monoclonal antibodies (MoAbs) directed against human superficial CD3, CD4, CD8, CD16, CD56, CD95 (Fas) CD178 (FasL) and CD45 antigens, (Becton Dickinson Immunocytometry Systems, Serotec) for 30 min in the dark, washed in PBS and resuspended in 300 μl of PBS with 1% formaldehyde. Internal control consisted of samples notstained and stained with negative isotype control (BDIS Tritest). Monoclonal set was alternatively modified for poor lymphocyte samples. FC data was acquired within 24 hours after staining, using argon ion laser 488 nm (FACSCalibur and FACScan cytometers, BDIS). The emitted light was detected through barrier filters specific for the emission range of the fluorochromes used in the study: 530/22 nm (fluorescence channel FL1) for FITC, 585/42 nm (FL2) for PE and > 650 nm (FL3) for PerCP. In each sample 8,000-12,000 cells were acquired. Alveolar macrophages (AM) and alveolar lymphocytes (AL) were gated according to cell granularity (side scatter, SSC) and intensity of CD45 staining. AL phenotype was yielded by dot plot quadrant analysis of respective fluorescence channels. AM FasL + percentage was determined by window analysis of the additional sample stained with MoAbs anti-CD178 PE/CD45 PerCP. The results were presented as the percentage of gated cells. Particulars are presented in Table 1 and Figure 1 [17, 20, 23] .
Statistics. Patient age and lung function test results were presented as mean ± SD, BAL phenotype and cytology results as a median ± SEM [23] . The Mann-Whitney U test was used to compare the data obtained in analyzed groups (untreated ILD patients vs. controls, smoker ILD subgroups vs. respective nonsmokers, corticosteroid treated PS patients vs. untreated ones). Spearman's rank correlation coefficient r s was applied to test the correlation between two random variables; p values of less than 0.05 were considered statistically significant.
Results
The information about age, gender, lung function tests and BAL fluid recovery in the nonsmoker groups, as well as their BAL cytology data, is summarized in Table 2 . Since restrictive ventilation pattern is characteristic for ILDs due to pulmonary fibrosis compli- BAL cytology results in the examined ILD groups, including the impact of tobacco consumption on BAL total cell count, cell composition, and CD4/CD8 index value, were typical for respective ILDs and consistent with previously published data [17] [18] [19] [20] [23] [24] [25] .
In nonsmokers we managed to gather sFasL results in all ILD groups (Figure 2 ). IPF and HP patients exhibited significantly higher sFasL levels, 2.04 ± ± 2.28 pg/ml (p = 0.043) and 13.0 ± 7.6 pg/ml (p = 0.019), respectively, compared to controls (0.21 ± ± 0.51 pg/ml). There were also relatively higher BAL sFasL concentrations in NSIP subjects, though the difference did not reach statistical significance (p = 0.072). Interestingly, sFasL levels observed in asbestosis were considerably increased. The limited number of analyzed patients hardly allows any interpretation, suggesting the need for further investigation.
Tobacco consumption resulted in a decline of median sFasL level in IPF smokers, compared to respective nonsmokers (p = 0.012). Corticosteroid therapy did not seem to affect sFasL levels in sarcoidosis patients: median values in PS stages II + III untreated and treated patients were similar.
AL immunotyping results are presented in Tables 3  and 4 . Contrary to the common belief that CD8 + lymphocytes in the lower airways exhibit an exclusively cytotoxic profile, a relatively high proportion of BAL CD4 + cells expressed Fas Ligand, both in ILD patients and in controls. Moreover, while a remarkable decline in the FasL + lymphocyte relative count was observed in HP and not-treated PS, CD8 + FasL + proportion was significantly higher in asbestosis and nonsmoking IPF, compared to controls. It is worth noting that in the corticosteroid treated PS group, considerably higher FasL + expression on AL and CD8 + cells in comparison with untreated PS was detected. As a rule, the proportion of AM Fas Ligand + was enhanced in most analyzed ILD groups, i.e. in nonsmoking PS patients stages II + III, both steroid treated and untreated, in IPF and in NSIP (respectively, 43 ± 5.5%, 51 ± 14.8%, 48 ± 8.8% and 43.5 ± 12.3% vs. 23 ± 13.6% in controls). A similar tendency, though not statistically significant, was observed in PS and IPF smokers in comparison with smoking controls. The median values of FasL expression on AM were significantly higher in IPF smokers than in respective nonsmoking patients (Figure 3) .
The analysis of FasL expression in the context of selected clinical and BAL cytologic data is summarized in Table 5 Results presented as median ± SEM; ≠p < 0.05 increased; Øp < 0.05 decreased compared to controls ), CD3 and CD95 expression. Close to 100% of AL expressed CD95 without any significant differences. Similarly, both in ILDs and controls, ~90% of AL were CD3 + with only a few NK cells [17, 23] . AL T and NK cell count did not correlate with lung function tests or FasL expression parameters.
Discussion
The close relationship between FasL and lung injury in acute lower airway disorders was proven long ago [9] . Some evidence has suggested also a direct link between pulmonary fibrosis and Fas Ligand expression in the lower airways. However, previously published studies concentrated mostly on IPF and collagen vascular diseases with concurrent ILD and examined levels of soluble FasL only. Surprisingly, patients' smoking status and ongoing therapy were not taken into account. Moreover, the examined groups were too small to provide credible data for statistical analysis. Still, Kuwano et al. were able to demonstrate that IPF and CVD patients referred for prednisolone therapy presented significantly higher sFasL levels in BAL supernatants, compared to those with a better prognosis and no indications to therapy [13] . Although the CVD group was not homogenous and definite recommendations for systemic corticosteroid therapy in IPF have not been yet established, the data presented by Kuwano et al. is of considerable importance.
Nonetheless, to the best of our knowledge, the current study is the first to provide simultaneous analysis of the membrane-bound and the soluble forms of FasL in the BAL material from the wide range of interstitial lung diseases with consideration to systemic corticosteroid treatment and the smoking status of the examined population.
The key finding presented here is the significantly higher concentration of sFasL observed in BAL supernatants of IPF and HP patients, with a tendency towards it in NSIP. We are the first to report this phenomenon in HP and NSIP groups, while data concerning IPF patients is in line with previous reports [13] . Not surprisingly, sFasL was not increased in sarcoidosis, which is infrequently complicated by lung fibrosis.
In our study, we suggest considerable FasL involvement in the pathogenesis of asbestosis. But as mentioned previously, a much larger group of patients needs to be evaluated in order to provide credible data.
In our opinion, the significant negative correlation between sFasL levels in BAL supernatants and lung function tests characterizing restriction pattern of ventilation disorders (VC % pred and DLCO % pred), as well as the relationship between VC % pred and membrane expression of FasL on AM and Tc cells demonstrated in the study, are of considerable inter- est. But these results should be reevaluated in the context of experimental data suggesting the complex role of FasL in inflammatory processes. Thus, soluble FasL levels might reflect the activation status of immune cells rather than the local pro-apoptotic capacity [3] . As mentioned above, the membrane-bound FasL form is potentially more efficient in triggering apoptosis of target cells than the soluble one. Such conclusions are supported by our results collected in smokers with IPF and corticosteroid treated PS patients. In the IPF smoker group, sFasL levels were comparable to the results detected in nonsmoking patients. Furthermore, while in many BAL samples of IPF smoking patients, sFasL concentration was undetectable, it is well known that there is a high risk of extremely unfavorable disease outcome in smokers [19] . In corticosteroid treated PS, contrary to our expectations, soluble FasL levels were not lower than in untreated counterparts.
Thus, the results presented in our study seem to disagree, at least to a certain extent, with the theoretical model of FasL pathogenetic role in IPF and other ILDs. Still, hypothetically, FasL + immune cells, including alveolar T cells, in particular T cytotoxic cells and alveolar macrophages, might comprise the most powerful pro-apoptotic and/or cytotoxic component of the FasL system expressed in lower airways. To the best of our knowledge, our study is the first to provide compelling analysis of FasL expression in AM population. Interestingly, experimental data seems to substantiate considerable AM pro-apoptotic activity against respiratory epithelia, higher than in other inflammatory cells [26] . According to our results, AM FasL + subpopulation was significantly increased in IPF (in particular in smokers, an IPF subgroup with an extremely poor prognosis), NSIP and stages II-III both treated and untreated PS patients.
In our study ILD entities characterized by Th1 prevalence and lymphocytic alveolitis, as HP and untreated PS, presented decreased FasL expression on alveolar Th and Tc cells. A strong correlation between sFasL levels and AL relative count was also observed. Therefore, we believe that the relationship between sFasL expression and BAL lymphocyte accumulation reported in some studies might reflect FasL shedding from the AL membrane rather than the direct impact of FasL on lymphocyte recruitment [1, 9] . Additionally, in our data, the highest proportion of AL FasL + was shown in IPF (for CD8) and asbestosis (for both CD8 and total AL). Also, PS patients on corticosteroid therapy (usually due to threatening lung fibrosis) presented higher AL FasL expression compared to untreated PS. The VC % pred values correlated negatively with both AM FasL + and Tc FasL + .
Consequently, we suggest that FasL + expression on alveolar lymphocytes and macrophages might reflect pro-apoptotic potential of local immune reaction, decisive for subsequent progression to lung fibrosis.
This concept is nicely supported by the strong correlation between FasL expression on AL, both CD4 + and CD8 + , and BAL neutrophil relative count demonstrated in our study. It is consistent with some previous reports of neutrophil recruitment by Fas Ligand to the inflammation site [27] . It has been shown as well that membrane-bound FasL could induce neutrophil infiltration in mice. Thus, FasL chemotactic activity towards human and murine neutrophils has been implicated, though the detailed mechanism remains uncertain [2] . Consequently, the correlation between BAL neutrophil number and FasL expression is an intriguing finding, as BAL neutrophilia, in contrast to lymphocytosis, is an important unfavorable prognostic factor in ILDs [17, 19, 28] . Our observations certainly require further investigation. However, they are important due to the possible practical applications [29] . Quite recently, Chung et al. proposed the inhibition of the Fas/FasL system as a successful treatment against septic shock. The rationale of such an approach was to block the excess of lymphocyte loss, and to limit neutrophil accumulation [30] .
In conclusion, it is worth emphasizing that our study provides compelling data demonstrating the upregulation of all FasL system components in IPF. However, we believe that the pathogenic role of FasL in other fibrosis-complicated ILDs, such as NSIP, asbestosis and advanced pulmonary sarcoidosis, is very likely as well. Most importantly, we provide data showing that tobacco consumption negatively affects sFasL soluble levels, but does not diminish the rate of sFasL + inflammatory cells in BAL. Finally, the presented results accentuate the potential role of FasL + alveolar lymphocytes and macrophages in Fas-dependent triggering of epithelial apoptosis and lung fibrosis, as well as suggesting that neutrophils and FasL + cytotoxic lymphocytes may act as triggers of lung fibrosis in ILDs.
